Septerna (SEPN) Competitors $11.69 +0.49 (+4.38%) Closing price 04:00 PM EasternExtended Trading$11.74 +0.05 (+0.43%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SEPN vs. DNLI, AGIO, CGON, MESO, HRMY, VCEL, BEAM, OCUL, ARQT, and TWSTShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Mesoblast (MESO), Harmony Biosciences (HRMY), Vericel (VCEL), Beam Therapeutics (BEAM), Ocular Therapeutix (OCUL), Arcutis Biotherapeutics (ARQT), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Its Competitors Denali Therapeutics Agios Pharmaceuticals CG Oncology Mesoblast Harmony Biosciences Vericel Beam Therapeutics Ocular Therapeutix Arcutis Biotherapeutics Twist Bioscience Denali Therapeutics (NASDAQ:DNLI) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation. Which has preferable earnings & valuation, DNLI or SEPN? Septerna has higher revenue and earnings than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali TherapeuticsN/AN/A-$422.77M-$2.80-5.29Septerna$1.08M482.32-$71.80MN/AN/A Does the media favor DNLI or SEPN? In the previous week, Septerna had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Septerna and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.81 beat Septerna's score of 0.29 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is DNLI or SEPN more profitable? Denali Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -12,053.03%. Septerna's return on equity of -35.82% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -39.15% -35.06% Septerna -12,053.03%-35.82%-24.65% Do insiders and institutionals believe in DNLI or SEPN? 92.9% of Denali Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 4.3% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate DNLI or SEPN? Denali Therapeutics currently has a consensus price target of $33.85, indicating a potential upside of 128.54%. Septerna has a consensus price target of $26.75, indicating a potential upside of 128.83%. Given Septerna's higher probable upside, analysts plainly believe Septerna is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.12Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryDenali Therapeutics and Septerna tied by winning 7 of the 14 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$520.91M$3.08B$5.63B$9.81BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-1.1620.6830.1125.79Price / Sales482.32329.08430.20159.26Price / CashN/A40.7837.7258.50Price / Book1.247.718.476.07Net Income-$71.80M-$54.65M$3.26B$265.11M7 Day Performance-0.51%3.95%3.56%2.90%1 Month Performance-0.34%11.46%5.97%3.99%1 Year PerformanceN/A13.04%42.70%26.92% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna1.6833 of 5 stars$11.69+4.4%$26.75+128.8%N/A$520.91M$1.08M-1.16N/ANews CoverageEarnings ReportDNLIDenali Therapeutics4.2037 of 5 stars$14.15-2.0%$33.85+139.2%-41.3%$2.06B$330.53M-5.32430News CoverageEarnings ReportGap UpAGIOAgios Pharmaceuticals4.3322 of 5 stars$35.10-2.9%$56.33+60.5%-20.9%$2.04B$40.88M3.20390Insider TradeCGONCG Oncology1.919 of 5 stars$26.43+1.3%$55.30+109.2%-24.2%$2.01B$1.14M-17.5161Earnings ReportUpcoming EarningsAnalyst RevisionMESOMesoblast1.5576 of 5 stars$15.54+0.7%$18.00+15.8%+133.1%$2.00B$5.90M0.0080Positive NewsHRMYHarmony Biosciences4.6787 of 5 stars$34.04-4.2%$51.00+49.8%+6.2%$1.94B$714.73M12.92200Analyst RevisionVCELVericel2.3616 of 5 stars$37.39-0.5%$59.86+60.1%-19.6%$1.86B$249.12M308.48300Positive NewsBEAMBeam Therapeutics2.5432 of 5 stars$18.39-3.8%$48.75+165.1%-29.7%$1.83B$63.52M-3.95510OCULOcular Therapeutix3.7297 of 5 stars$11.72-5.1%$17.33+47.9%+56.2%$1.81B$63.72M-9.90230ARQTArcutis Biotherapeutics2.7488 of 5 stars$15.25+5.0%$19.40+27.3%+55.3%$1.80B$196.54M-14.48150Positive NewsEarnings ReportAnalyst RevisionTWSTTwist Bioscience3.5409 of 5 stars$29.98-0.8%$50.40+68.1%-35.7%$1.80B$312.97M-9.22990 Related Companies and Tools Related Companies DNLI Competitors AGIO Competitors CGON Competitors MESO Competitors HRMY Competitors VCEL Competitors BEAM Competitors OCUL Competitors ARQT Competitors TWST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access